These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 31856887)
1. A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial. Bradley JM; Anand R; O'Neill B; Ferguson K; Clarke M; Carroll M; Chalmers J; De Soyza A; Duckers J; Hill AT; Loebinger MR; Copeland F; Gardner E; Campbell C; Agus A; McGuire A; Boyle R; McKinney F; Dickson N; McAuley DF; Elborn S; Trials; 2019 Dec; 20(1):747. PubMed ID: 31856887 [TBL] [Abstract][Full Text] [Related]
2. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Welsh EJ; Evans DJ; Fowler SJ; Spencer S Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010337. PubMed ID: 26171905 [TBL] [Abstract][Full Text] [Related]
3. Saline in acute bronchiolitis RCT and economic evaluation: hypertonic saline in acute bronchiolitis - randomised controlled trial and systematic review. Everard ML; Hind D; Ugonna K; Freeman J; Bradburn M; Dixon S; Maguire C; Cantrill H; Alexander J; Lenney W; McNamara P; Elphick H; Chetcuti PA; Moya EF; Powell C; Garside JP; Chadha LK; Kurian M; Lehal RS; MacFarlane PI; Cooper CL; Cross E Health Technol Assess; 2015 Aug; 19(66):1-130. PubMed ID: 26295732 [TBL] [Abstract][Full Text] [Related]
4. Nebulised hypertonic saline for cystic fibrosis. Wark P; McDonald VM; Smith S Cochrane Database Syst Rev; 2023 Jun; 6(6):CD001506. PubMed ID: 37319354 [TBL] [Abstract][Full Text] [Related]
5. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Tam J; Nash EF; Ratjen F; Tullis E; Stephenson A Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007168. PubMed ID: 23852992 [TBL] [Abstract][Full Text] [Related]
6. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Kellett F; Robert NM Respir Med; 2011 Dec; 105(12):1831-5. PubMed ID: 22018993 [TBL] [Abstract][Full Text] [Related]
7. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Nicolson CH; Stirling RG; Borg BM; Button BM; Wilson JW; Holland AE Respir Med; 2012 May; 106(5):661-7. PubMed ID: 22349069 [TBL] [Abstract][Full Text] [Related]
8. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B; Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664 [TBL] [Abstract][Full Text] [Related]
9. Nebulised 3% hypertonic saline versus 0.9% saline for treating patients hospitalised with acute bronchiolitis: protocol for a randomised, double-blind, multicentre trial. Szupieńko S; Buczek A; Szymański H BMJ Open; 2023 Nov; 13(11):e080182. PubMed ID: 38011984 [TBL] [Abstract][Full Text] [Related]
10. Timing of hypertonic saline inhalation for cystic fibrosis. Elkins M; Dentice R Cochrane Database Syst Rev; 2012 Feb; (2):CD008816. PubMed ID: 22336853 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Kellett F; Redfern J; Niven RM Respir Med; 2005 Jan; 99(1):27-31. PubMed ID: 15672845 [TBL] [Abstract][Full Text] [Related]
12. Impact of hypertonic saline nebulisation combined with oscillatory positive expiratory pressure on sputum expectoration and related symptoms in cystic fibrosis: a randomised crossover trial. San Miguel-Pagola M; Reychler G; Cebrià I Iranzo MA; Gómez-Romero M; Díaz-Gutiérrez F; Herrero-Cortina B Physiotherapy; 2020 Jun; 107():243-251. PubMed ID: 32026826 [TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
14. Nebulised hypertonic saline for cystic fibrosis. Wark PA; McDonald V; Jones AP Cochrane Database Syst Rev; 2005 Jul; (3):CD001506. PubMed ID: 16034863 [TBL] [Abstract][Full Text] [Related]
15. Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial. Herrero-Cortina B; Alcaraz V; Vilaró J; Torres A; Polverino E J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):281-289. PubMed ID: 29878856 [TBL] [Abstract][Full Text] [Related]
16. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study. Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503 [TBL] [Abstract][Full Text] [Related]
17. Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trial. Chang AB; Yerkovich ST; Baines KJ; Burr L; Champion A; Chatfield MD; Eg KP; Goyal V; Marsh RL; McCallum GB; McElrea M; McPhail S; Morgan LC; Morris PS; Nathan AM; O'Farrell H; Sanchez MO; Parsons M; Schultz A; Torzillo PJ; West NP; Versteegh L; Marchant JM; Grimwood K BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38719503 [TBL] [Abstract][Full Text] [Related]
18. Nebulised dornase alfa versus placebo or hypertonic saline in adult critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Claudius C; Perner A; Møller MH Syst Rev; 2015 Nov; 4():153. PubMed ID: 26547839 [TBL] [Abstract][Full Text] [Related]